Prisyna is a technology company.
Prisyna has raised $6.0M across 1 funding round.
Prisyna has raised $6.0M in total across 1 funding round.
Prisyna has raised $6.0M in total across 1 funding round.
Prisyna's investors include 1Flourish Capital, A Capital, Advisors Fund LLC, Caffeinated Capital, CRV, Zachary Bogue, IDG Ventures, Practical Venture Capital, Alexander Rosen, Streamlined Ventures, Uncork Capital, Akash Garg.
Prisyna is a biotechnology-driven oral care company that developed advanced mouth rinses using proprietary glycomics technology combined with natural materials and polysaccharides to clean teeth and gums, freshen breath, and moisten mouths without abrasion or irritation.[2][3] It targeted conditions like dry mouth and oral mucositis, serving consumers and dentists through products such as Synedent Oral Care and Synedent Plus, available online and via dental professionals.[2] Operating as an independent business unit within Synedgen—a biotech firm focused on polysaccharide-based drugs—Prisyna secured $6 million in equity financing in 2018 to expand its pipeline, but ceased operations during COVID-19, with Synedgen licensing its chitosan rinse technology exclusively to PerioSciences.[4][8]
Prisyna was founded in 2013 by Shenda Baker, Ph.D., with William Wiesmann, M.D., as co-founder and leader, building on Synedgen's glycomics platform to apply biotech innovations to consumer oral care.[1][2] The idea emerged from Synedgen's expertise in polysaccharides for pharmaceuticals, extending it to oral health products that support a healthy oral cavity without the burn of traditional rinses.[2][6] Early traction included launching Synedent products and securing $6 million in financing by 2018 from new and existing investors to fuel growth as a distinct Synedgen unit, with plans for an expanded leadership team.[2][4]
Prisyna rode the trend of biotech converging with consumer health, applying pharmaceutical-grade glycomics to everyday oral care amid rising demand for natural, non-irritating alternatives to chemical-heavy products.[2][3] Timing aligned with growing awareness of oral-systemic health links, like mucositis in cancer patients and dry mouth from medications, where market forces favored innovation over traditional dentistry.[2] It influenced the ecosystem by demonstrating how biotech platforms like Synedgen's could spawn consumer units, paving the way for licensed technologies post-shutdown, as seen with PerioSciences' exclusive chitosan rinses.[6][8]
Prisyna's legacy endures through its licensed technology, now advancing under PerioSciences, potentially expanding chitosan-based rinses globally amid post-COVID biotech resilience and personalized oral care trends.[8] Evolving demands for biotech wellness solutions—driven by aging populations and microbiome research—could amplify its influence, with Synedgen's platform enabling further oral health innovations. This pivot from standalone operation to licensed asset underscores adaptive biotech models in consumer markets.
Prisyna has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in April 2016.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2016 | $6.0M Seed | 1Flourish Capital, A Capital, Advisors Fund LLC, Caffeinated Capital, CRV, Zachary Bogue, IDG Ventures, Practical Venture Capital, Alexander Rosen, Streamlined Ventures, Uncork Capital, Akash Garg, Anil Dharni, Anthony Soohoo, Dharmesh Shah, Eric Ries, James Hong, Jonathan Boutelle, Marc Benioff, Matt Cutts, Matt Mazzeo, Narendra Rocherolle, Othman Laraki, Philip Kaplan, Ronny Conway, Russell Fradin, Russ Fradin, Ryan Spoon |